Research
Hormonal
Muscle function (strength and power) declines at a substantially faster rate than muscle mass, with power loss beginning as early as young adulthood (20-39 years).
Prioritize power training (moving weight quickly) in addition to strength training. Since power loss starts in your 20s and 30s, maintaining explosive movement capability is key to preventing future frailty and falls.
GoodSupportsHIGH confidence
indices of muscle function (most notably strength and power) decline at a much faster rate... cited values of ~1% /year for SKM mass losses beyond the age of 70 compared with >3% for strength... declines in muscle power could be seen in the youngest cohort (20–39 years) for both sexes
Why this rating
Supported by multiple longitudinal studies cited in the review.
Source
Skeletal muscle dysfunction with advancing age
Pardeep Pabla et al. · Clinical Science · 2024
DOI 10.1042/cs20231197
narrative_reviewCited 28×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Skeletal muscle mass loss with advancing age is primarily driven by anabolic resistance (blunted muscle protein synthesis response to protein and exercise) rather than increased protein breakdown, with losses accelerating after the 7th decade of life.Good
- Physical inactivity and hospitalization-induced bed rest accelerate muscle mass and function loss in older adults at a rate 3-6 times faster than in younger adults, with incomplete recovery.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →